
What smart money is saying about LivaNova PLC
2 funds in our archive have pitched LivaNova PLC — most recently Artisan Partners Non-U.S. Small-Mid Growth Strategy in June 2026.
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Get an email when a fund writes about it
Position history
Between Q4 2025 and Q2 2026, 1 fund letter reported a position in LivaNova PLC, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 0 | 1 |
| Q4 2025 | 0 | 0 | 0 | 1 |
Fund activity · 1 position
- HoldsArtisan Partners Non-U.S. Small-Mid Growth StrategyJune 2026
“Our top contributors for the quarter were Rohm, LivaNova and Glanbia.”
Read the letterLivaNova PLC
Fund coverage · 2 theses
- Artisan Partners Non-U.S. Small-Mid Growth StrategyJune 2026
LivaNova combines dominant cardiopulmonary market share, a growing neuromodulation business and an approved sleep-apnea pipeline with long growth runway.
Read the full thesis - Artisan Non-U.S. Small-Mid Growth StrategyDecember 2025
LivaNova PLC is a medtech leader with dominant cardiopulmonary share, improving execution under new leadership, and meaningful neuromodulation pipeline optionality.
Read the full thesis
Read every full thesis on LivaNova PLC
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→